MannKind | MNKD - Cash And Equivalent


MannKind reported $127.39M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Adma Biologics USD 61.38M 28.9M Sep/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Insmed USD 510.44M 175.68M Dec/2025
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
MannKind USD 127.39M 70.39M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Minerva Neurosciences USD 12.29M 2.96M Sep/2025
Novavax USD 268.02M 14.28M Sep/2025
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Pfizer USD 1.34B 295M Sep/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Xencor USD 54.07M 25.78M Dec/2025